LILLY (ELI) & COMPANY: LLY Q1 2013 Dividend, $1.5B Share Repurchase Program

LILLY (ELI) & COMPANY: LLY Q1 2013 Dividend, $1.5B Share Repurchase Program
Date: December 17, 2012                                                         
For Release: Immediately 
Refer to: (317) 276-5795 Mark Taylor 
 Lilly Declares First-Quarter 2013 Dividend, Announces New $1.5 Billion Share   
                          Repurchase Program                                
The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a
dividend for the first quarter of 2013 of $0.49 per share on outstanding common
stock. The dividend is payable March 8, 2013 to shareholders of record at the
close of business on February 15, 2013. 
The Lilly board of directors also authorized the initiation of a new $1.5
billion share repurchase program, which the company anticipates completing in
2013. The company recently completed a $3.0 billion share repurchase program
that was started in 2000. All purchases under the new $1.5 billion share
repurchase program will be made on the open market at prevailing prices.
Purchases will be made over a period to be determined by management of the
company. Shares acquired will be retired. 
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -
through medicines and information - for some of the world's most urgent medical
needs. Additional information about Lilly is available at 
This press release contains forward-looking statements that are based on
management's current expectations, but actual results may differ materially due
to various factors. There is no guarantee the company will be able to complete
its planned 2013 share repurchases. There are significant risks and
uncertainties in pharmaceutical research and development. There can be no
guarantees with respect to pipeline products that the products will receive the
necessary clinical and manufacturing regulatory approvals or that they will
prove to be commercially successful. Pharmaceutical products can develop
unexpected safety or efficacy concerns. The company's results may also be
affected by such factors as competitive developments affecting current
products; market uptake of recently launched products; the timing of
anticipated regulatory approvals and launches of new products; regulatory
actions regarding currently marketed products; issues with product supply;
regulatory changes or other developments; regulatory compliance problems or
government investigations; patent disputes; changes in patent law or
regulations related to data-package exclusivity; other litigation involving
current or future products; the impact of governmental actions regarding
pricing, importation, and reimbursement for pharmaceuticals, including U.S.
health care reform; changes in tax law; asset impairments and restructuring
charges; acquisitions and business development transactions; and the impact of
exchange rates and global macroeconomic conditions. For additional information
about the factors that affect the company's business, please see the company's
latest Form 10-Q and Form 10-K filed with the U.S. Securities and Exchange
Commission. The company undertakes no duty to update forward-looking

                                     # # #                                     

Eli Lilly and Company

Lilly Corporate Center

Indianapolis, Indiana 46285

                                     - 2 -                                     

-0- Dec/18/2012 07:00 GMT

Press spacebar to pause and continue. Press esc to stop.